Docket No.: **SAEG143.002AUS** Page 1 of 2



Please Direct All Correspondence to Customer Number 20995

AMENDMENT / RESPONSE TRANSMITTAL

Tamaki et al.

App. No

10/748,490

Filed

December 30, 2003

For

AGENT FOR PREVENTION AND

TREATMENT OF INFLAMMATORY

BOWEL DISEASE

Examiner

Unknown

Art Unit

1614

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

February 3, 2006

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing in the above-identified application are the following enclosures:

- Notice to Comply. (X)
- (X) Response to Notice to Comply in 2 pages.
- (X) Substitute Sequence Submission Statement in 1 page; paper copy of Sequence Listing in 2 pages; Sequence Listing in CRF.

The fee has been calculated as shown below:

The present application qualifies for Small Entity Status under 37 CFR 1.27.

FEE CALCULATION								
FEE TYPE						FEE CODE	CALCULATION	TOTAL
Excess Claims	• 11	-	20	=	0	2202 (\$25)	0 x 25 =	\$0
Excess Independent	2	-	3	=	0	2201 (\$100)	0 x 100 =	\$0
Multiple Claim	1.16(j)					2203 (\$180)		\$0
							TOTAL FEE DUE	\$0

Return prepaid postcard. (X)

Docket No.: SAEG143.002AUS

App. No.: 10/748,490

February 3, 2006

Page 2 of 2

Please Direct All Correspondence to Customer Number 20995

(X) Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Eric Ives

Registration No. 50,928

Agent of Record

Customer No. 20,995

(805) 547-5580

2349042:vr 020306



Inited States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Sox 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NUMBER FIRST NAMED APPLICANT FILING OR 371 (c) DATE ATTORNEY DOCKET NUMBER 10/748,490 Hiroyuki Tamaki

12/30/2003

SAEG143.002AUS

20995 KNOBBE MARTENS OLSON & BEAR LLP 2040 MAIN STREET **FOURTEENTH FLOOR IRVINE, CA 92614**

CONFIRMATION NO. 8746 FORMALITIES LETTER

Date Mailed: 12/06/2005

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

 A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

To Download Patentin Software, visit http://www.uspto.gov/web/patents/software.htm For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Replies should be mailed to:

Mail Stop Missing Parts

Commissioner for Patents

P.O. Box 1450

Alexandria VA 22313-1450

Office of Initial Patent Examination (571) 272-4000, or 1-800-PTO-9199, or 1-800-972-6382

PART 2 - COPY TO BE RETURNED WITH RESPONSE